Ezetimibe/rosuvastatin
 Ezetimibe (top) and rosuvastatin (bottom) | |
| Combination of | |
|---|---|
| Ezetimibe | Hypolipidemic agent |
| Rosuvastatin | Statin |
| Clinical data | |
| Trade names | Ridutrin,Cholerose Plus, Lipocomb, Rosuzet, others[1][2] |
| AHFS/Drugs.com | Multum Consumer Information |
| License data | |
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
Ezetimibe/rosuvastatin, sold under the brand name Ridutrin among others, is a combination medication used to treat high cholesterol.[6][7] In some countries it is sold as a kit or a pack containing two distinct pills.[8][1]
The combination was approved for medical use in the United States in March 2021.[5]
Medical uses
Ezetimibe/rosuvastatin is indicated as an adjunct to diet in people with primary non-familial hyperlipidemia to reduce low-density lipoprotein cholesterol (LDL-C); and alone or as an adjunct to other LDL-C-lowering therapies in people with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C.[9]
Pharmacology
Ezetimibe/rosuvastatin combines two lipid-lowering therapies with distinct actions to achieve greater lowering of LDL-C that either agent alone.
- Ezetimibe inhibits NPC1L1, the transporter that is responsible for absorption of dietary cholesterol from the intestine.[10]
- Rosuvastatin inhibits HMG-CoA reductase, an enzyme involved in synthesis of new cholesterol in the liver.[10]
Together, these drugs cause a net decrease in hepatocyte intracellular cholesterol leading to scavenging of LDL particles from the blood via upregulation of the LDL receptor.
References
- ^ a b "Rosuvastatin international". Drugs.com. 3 February 2020. Retrieved 17 February 2020.
- ^ a b "Ezetimibe/rosuvastatin: List of nationally authorised medicinal products" (PDF). European Medicines Agency (EMA). 21 March 2018. PSUSA/00010271/201707. Retrieved 17 February 2020.
- ^ a b "TGA eBS - Product and Consumer Medicine Information Licence".
- ^ "EZESTAT COMPOSITE PACK (Pharmacor Pty Ltd)". Department of Health and Aged Care. Archived from the original on 18 March 2023.
- ^ a b "Roszet: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 24 March 2021.
- ^ "Ridutrin SmPC" (PDF). Medicines Data Bank. 30 May 2019. Retrieved 17 February 2020.
- ^ Willihnganz MJ, Gurevitz SL, Clayton BD (November 2021). "HMG-CoA Reductase Inhibitor Combination Products". Clayton's Basic Pharmacology for Nurses - E-Book. Elsevier Health Sciences. p. 344. ISBN 978-0-323-81258-0.
- ^ "Rosuzet Composite Pack". NPS MedicineWise. 8 January 2020. Retrieved 17 February 2020.
- ^ Sharretts J (23 March 2021). "NDA Approval Letter for Roszet (rosuvastatin and ezetimibe)" (PDF). Center for Drug Evaluation and Research. U.S. Food and Drug Administration.
- ^ a b "DailyMed - ROSZET- rosuvastatin and ezetimibe tablet ROSZET (- rosuvastatin and ezetimibe tablet". dailymed.nlm.nih.gov. Retrieved 14 January 2024.
External links
- "Ridutrin (rosuvastatin zinc/ezetimibe) Public Assessment Report Scientific discussion" (PDF). NL/H/3017/001-003/DC.
 | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
- Articles with short description
- Short description matches Wikidata
- Use dmy dates from February 2020
- Drugs with non-standard legal status
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Drugs that are a combination of chemicals
- Combination lipid-lowering drugs
- All stub articles
- Cardiovascular system drug stubs